Navigation Links
Common treatment for chronic prostatitis fails to reduce symptoms
Date:12/18/2008

Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The study is to be published in the New England Journal of Medicine.

"Although these results are disappointing, it is just as important to find out what doesn't work as it is to know what does," said NIDDK Director Griffin P. Rodgers, M.D. "We have conclusively shown that a drug commonly prescribed for men with chronic prostatitis did not significantly reduce symptoms compared to a placebo."

Chronic prostatitis, which has no known cause and no uniformly effective therapy, is the most common type of prostatitis seen by physicians. Men with this condition experience pain in the genital and urinary tract areas, lower urinary tract symptoms such as pain in the bladder area and during urination, and sexual problems that can severely affect their quality of life. Population-based surveys estimate that 6 percent to 12 percent of men have prostatitis-like symptoms.

A total of 272 men diagnosed with chronic prostatitis were randomly assigned to take either alfuzosin or an identical-looking placebo. Of these, 233 men completed the trial. The primary outcome was a decrease (improvement) in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) of at least four points over 12 weeks of treatment. A 4-point decrease in the NIH-CPSI score has been shown to be the minimal clinically significant difference perceived by patients as beneficial. The index measures the three most important symptoms of chronic prostatitis pain, problems with urination, and negative effects on quality of life.

The
'/>"/>

Contact: Arthur Stone
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)..., The copper sequestering drug tetrathiomolybdate... the treatment of Wilson disease, a disease caused...cancers. That much is known. Very little, however,...r level. , A new study led by Northwestern Unive...lue: the three-dimensional structure of TM bound t...
(Date:11/26/2009)..., No more letters from th...or,personalized text messages from Santa , ...effort to increase operational efficiencies at the...ng to help keep children all over the globe inform... ,Elves in Santa’s research department have ...
(Date:11/26/2009)..., Benton Communications a...iness growth system for retailers struggling to ma... (PRWEB) November 26, 2009 -- Flu fears is the ty...es to the emergency room, according to Dr. David B...wly released business growth system – The R...
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBar...ion,slargestmedicalcliniconDec.9-10,whenKansasCity...suredpeople. ,, "Thisfreecliniceventhasthepoten...odaysinsteadofjustoneandbeheldonweekdaysinsteadofo...sCityFreeHealthClinicandpresidentoftheNationalAsso...
(Date:11/25/2009)...,, TORONTO,Nov.25/PRNewswire/-SentinelleMedi...ancedvisualizationsoftwarelaunchesasuiteofnewleadi...gingsoftwareplatformatthisyear,sRadiologicalSociet...-Dec.5,2009(Booth5800,HallA).Theapplicationslevera...sspecializedMRIimagingcoilsandsupportmultipleimagi...
Breaking Medicine News(10 mins):Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3
...IHE, and BCBSA Target April 2009 Interoperability ...ng Project Demonstration , , WASHINGTON, Jan. 5 ...nounced today they are collaborating with the Cent...tions implementation. The organizations include C...
...ars to delay dangerous heart muscle expansion in m... ,Tests in mouse hearts show that sildenafil, the ...amage caused by high blood pressure, a new study s...s blood-pumping function from spiraling into heart...
...a., Jan. 5 Governor Edward G. Rendell expressed d...ministration -- now in their waning days -- would ...tient care and limit a woman,s access to medical t...that could have serious, detrimental impacts on pa...
...an. 5 Resolving to eat more fish, which contain,l... sage advice for most,consumers, especially for th...rch. The December 2008 Fats of Life and PUFA News...alian study with nearly 7,000 heart failure patien...
... Jan. 5 The Mobile Massage Team ( www.mobilemassa... massage services for corporate wellness programs,... eleven new team members to its therapist roster i...ge Team. "They reflect the continued growth of our...
...N.Y., Jan. 5 Misonix, Inc. (Nasdaq: MSON ), a d...device technology, which in Europe is used for the...health conditions, has entered into a definitive, ... interim agreement announced on November 7, 2008. ...
Other Medicine News:Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 2Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 3Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 4Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 5Health News:Viagra May Shield Heart From Blood Pressure Damage 2Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 2Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 3Health News:Eating More Fish a Wise New Year Resolution, Studies Show 2Health News:Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region 2Health News:Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region 3Health News:Misonix Announces New HIFU Distribution Agreement for Italy 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 3
(Date:11/25/2009)...Calif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,ann...ny,sPROTECT-1(theProspectiveRandomizedOralTherapyE...CX282-B)inpatientswithmoderate-to-severeCrohn,sdis...tyandtolerabilityprofile.Thestudydemonstratedevide...tyasdefinedasa70-pointdecreaseintheCrohn,sDiseaseA...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Endologix,Inc.(Nasd...oraorticdisorders,announcedtodaythatithasfiledamot...nfringementlawsuitbroughtagainstitinOctober2009byC...CourtinIndianapolis,Indiana. ,, Endologixhasreq...sPatentandTrademarkOffice(USPTO)conductsproceeding...
(Date:11/24/2009)...24/PRNewswire-FirstCall/--AnadysPharmaceuticals,In...the21stAnnualPiperJaffrayHealthcareConferenceonTue...onferenceisbeingheldatTheNewYorkPalaceHotel.SteveW...adys,willprovideanoverviewofAnadysanditsclinicalde...atepresentationwillbesimultaneouslywebcastandcanbe...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2AMT Provides Business Update for the Third Quarter 2009 14895 1AMT Provides Business Update for the Third Quarter 2009 14895 2AMT Provides Business Update for the Third Quarter 2009 14895 3AMT Provides Business Update for the Third Quarter 2009 14895 45 exercises can reduce neck shoulder pain of women office workers 10780 15 exercises can reduce neck shoulder pain of women office workers 10780 25 exercises can reduce neck shoulder pain of women office workers 10780 3BioSoteria CEO to Present at Drug Safety Conference 14889 1BioSoteria CEO to Present at Drug Safety Conference 14889 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
Atria 3100 ECG
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: